IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Amer Methqal Zeidan, Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Mikkael A. Sekeres, Michael R. Savona, Yazan F. Madanat, Maria Diez-Campelo, David Valcarcel, Thomas Illmer, Anna Jonasova, Petra Belohlavkova, Laurie Jill Sherman, Tymara Berry, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Fei Huang, Rami S. Komrokji
Institutions: Yale Cancer Center, Yale University, University Hospital Leipzig, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Hôpital Saint-Louis, Université Paris Diderot, University of Miami, Sylvester Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Universidad de Salamanca, Complejo Hospitalario de Salamanca, Vall d'Hebron Hospital Universitari, University Hospital Hradec Králové, Geron (United States), Moffitt Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379340614